Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Angiogenesis as a hallmark of solid tumors - clinical perspectives

(2021) Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cellular Oncology.

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Background: Angiogenesis is a key and early step in tumorigenesis, and is known as a hallmark of solid tumors and a key promoter of tumor recurrence. Unlike normal tissue vessels, the architecture of the tumor vasculature is abnormal, being leaky, tortuous, fragile and blind-ended. Perivascular cells are either detached or absent, causing reduction of vascular integrity, an increase in vessel immaturity, incoherent perfusion, defective functionality and enhanced tumor dissemination and metastasis. The abnormal tumor vasculature along with the defective tumor vessel functionality finally causes bouts of hypoxia and acidity in the tumor microenvironment (TME), further reinvigorating tumor aggression. Interstitial hypertension or high interstitial fluid pressure (IFP) is an outcome of tumor hyper-permeability. High IFP can be a barrier for either effective delivery of anti-cancer drugs toward the TME or accumulation of drugs within the tumor area, thus promoting tumor resistance to therapy. Some tumors do, however, not undergo angiogenesis but instead undergo vessel co-option or vascular mimicry, thereby adding another layer of complexity to cancer development and therapy. Conclusions: Combination of anti-angiogenesis therapy with chemotherapy and particularly with immune checkpoint inhibitors (ICIs) is a promising strategy for a number of advanced cancers. Among the various approaches for targeting tumor angiogenesis, vascular normalization is considered as the most desired method, which allows effective penetration of chemotherapeutics into the tumor area, thus being an appropriate adjuvant to other cancer modalities. © 2021, Springer Nature Switzerland AG.

Item Type: Article
Keywords: Angiogenesis; Bevacizumab; Cancer stem cell (CSC); Chemotherapy; Combination therapy; Endothelial cell (EC); Hypoxia; Normalization; Pazopanib; Pericyte; Programmed death-1 receptor (PD-1); Programmed death-ligand 1 (PD-L1); Sunitinib; Tumor microenvironment (TME); Vascular endothelial growth factor (VEGF); Vascular mimicry; Vessel co�option
Subjects: QS Human Anatomy > QS1-132 Anatomy
Divisions: Education Vice-Chancellor Department > Faculty of Medicine > Department of Basic Science > Department of Histology and Anatomy
Journal or Publication Title: Cellular Oncology
Journal Index: ISI
Publisher: Springer Science and Business Media B.V.
Identification Number: 10.1007/s13402-021-00602-3
ISSN: 22113428
Depositing User: مسعود رسول آبادی
URI: http://eprints.muk.ac.ir/id/eprint/5030

Actions (login required)

View Item View Item